Minapharm has established six manufacturing sites, including two expansions in Cairo and Berlin that cater to the development and end-to-end manufacturing of advanced biologics’ therapies.
Established in the early 90’s, Minapharm prime facility is headquartered in Cairo, Egypt. The fully automated factory relies on state-of-the-art machinery to deliver more than 150 life-saving and life-enhancing medicines. These range from small molecules to extremely complex bioengineered products.
At the Minapharm’s prime facility, proprietary licensed products as well as generics and unique galenic formulations are manufactured. Minapharm also produces line extensions in multiple dosage forms to accommodate a diverse array of needs.
Minapharm Prime facility complies with current Good Manufacturing Practice regulations (CGMPs), ISO standards, World Health Organization (WHO), and other international standards regulating the pharmaceutical industry.
MiGenTra Egypt is the first R&D and biopharmaceutical manufacturing facility in Egypt, Africa, and the Middle East. The facility specializes in the development and manufacture of therapeutic recombinant proteins and vaccines and is primarily focused on liver disease, thrombosis and haemostasis, infertility, oncology, and rheumatoid arthritis.
Established more than 25 years ago, ProBioGen is a contract development and manufacturing organization (CDMO) and technology provider located in Berlin, Germany. The company specializes in the development and manufacture of complex therapeutic proteins. The facility and its expansion include state-of-the-art GMP production sites.
Established in 2022, Minapharm’s factory of the future is the first cell and gene therapy manufacturing facility in Africa and the Middle East. Located in Egypt, it specializes in the production of advanced therapies and medicinal products in the biotechnology sector. The facility complies with EMA standards and is equipped with tens of thousands of liter fermenters.
